Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 in moderate to severe seasonal allergic rhinitis
NCT06046391Phase 2Completed
- Sponsor
- LongBio Pharma
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LP-003 in seasonal allergic rhinitis (SAR) (3 arms), sponsored by LongBio Pharma. Primary endpoint: Mean Nasal Symptom Score. Started Jul 2023; status: completed.
02
Drugs
LP-003
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT06046391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046391.